Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Massachusetts General Hospital

Sites in Boston, MA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 4:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1483
Shown on this page
12
Current sort
Recently updated
Campus scope
Massachusetts General Hospital, Boston, MA
Additional filters apply within this campus.

The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.

Filter and sort this campus

These controls apply only within Massachusetts General Hospital, Boston, MA. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 313–324 of 1,483 matching trials with a site at Massachusetts General Hospital, Boston, MA.
Indexed local directory records.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Stored official records

Active, not recruiting Phase 2 Interventional

Genetic Testing in Guiding Treatment for Patients With Brain Metastases

NCT03994796
Site status not listed — check the official record
View directory record Official record
Conditions
CDK Gene Mutation, KRAS G12C Mutation, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, NTRK Family Gene Mutation, PI3K Gene Mutation, ROS1 Gene Mutation
Interventions
Abemaciclib, Adagrasib, Entrectinib, PI3K Inhibitor paxalisib
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
435
States / cities
Anchorage, Alaska • Phoenix, Arizona • Scottsdale, Arizona + 306 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 15, 2026, 11:16 AM EDT
Recruiting Not applicable Interventional

Treatment in Thoracic Aortic Aneurysm: Surgery vs Surveillance

NCT03536312
Status at this site: Recruiting
View directory record Official record
Conditions
Ascending Aorta Aneurysm, Ascending Aortic Aneurysm Enlargement
Interventions
Thoracic Aortic Surgery
Procedure
Lead sponsor
Ottawa Heart Institute Research Corporation
Other
Eligibility
18 Years to 79 Years
Enrollment
610 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2035
U.S. locations
16
States / cities
San Francisco, California • Iowa City, Iowa • Boston, Massachusetts + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Sep 29, 2026, 10:11 PM EDT
Active, not recruiting No phase listed Observational

Pyruvate Kinase Deficiency Global Longitudinal Registry

NCT03481738
Site status not listed — check the official record
View directory record Official record
Conditions
Pyruvate Kinase Deficiency
Interventions
Not listed
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
Not listed
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
15
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Orange, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 18, 2026, 4:43 PM EDT
Not yet recruiting Not applicable Interventional

Sleep Harmonization Via Bundled Team-Based Interventions in the ICU

NCT07840560
Site status not listed — check the official record
View directory record Official record
Conditions
Bundle Care, Critical Illness, Delirium, Implementation Science, Sleep Deprivation, Sleep-Wake Disorders
Interventions
Clustering patient-care interactions, Daytime light exposure, Encourage out-of-bed activity, Medication management to support nighttime sleep, Nighttime noise & light reduction, Non-pharmacologic sleep aids
Behavioral · Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
62,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
7
States / cities
La Jolla, California • San Francisco, California • Orlando, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Sep 29, 2026, 10:11 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

GBPDC: Gut-Brain in PD Consortium Master Protocol

NCT07567794
Status at this site: Recruiting
View directory record Official record
Conditions
Gut Microbiome, Gut Microbiota, PARKINSON DISEASE (Disorder), Parkinson Disease (PD), Prodromal Parkinsons Disease
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
21 Years to 80 Years
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
7
States / cities
Stanford, California • Chicago, Illinois • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Sep 29, 2026, 10:11 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma

NCT07266441
Site status not listed — check the official record
View directory record Official record
Conditions
Multiple Myeloma
Interventions
JNJ-79635322
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
30
States / cities
Birmingham, Alabama • Gilbert, Arizona • Duarte, California + 24 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 14, 2026, 10:20 PM EDT
Active, not recruiting Early Phase 1 Interventional

Tolerance Through Mixed Chimerism (Sip-Tego)

NCT06972069
Site status not listed — check the official record
View directory record Official record
Conditions
Immunosuppresion, Immunosuppression After Kidney Transplantation, Kidney Failure, Transplant Recipient (Kidney), Transplant Tolerance
Interventions
Combined Kidney/Bone Marrow Transplant, Conditioning Regimen (Rituxan, Siplizumab (or ATGAM), Cyclophosphamide, Tegoprubart), Donation of Kidney / Bone Marrow
Procedure · Drug
Lead sponsor
Tatsuo Kawai, MD, PhD
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Sep 29, 2026, 10:11 PM EDT
Recruiting Phase 1 Interventional

Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer

NCT06801236
Status at this site: Recruiting
View directory record Official record
Conditions
Prostate Cancer (Adenocarcinoma), mCRPC (Metastatic Castration-resistant Prostate Cancer)
Interventions
ACE-232 tablets
Drug
Lead sponsor
Acerand Therapeutics (Hong Kong) Limited
Industry
Eligibility
18 Years and older · Male only
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
8
States / cities
La Jolla, California • Tampa, Florida • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Sep 30, 2026, 8:14 PM EDT
Recruiting Phase 3 Interventional

Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

NCT06561048
Status at this site: Recruiting
View directory record Official record
Conditions
Angioimmunoblastic T-cell Lymphoma, Follicular T-Cell Lymphoma, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Peripheral T-Cell Lymphoma, Not Otherwise Specified, Systemic Anaplastic Large Cell Lymphoma
Interventions
Belinostat, Pralatrexate, Soquelitinib
Drug
Lead sponsor
Corvus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
24
States / cities
Duarte, California • Irvine, California • San Francisco, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 15, 2026, 6:10 AM EDT
Recruiting Phase 4 Interventional

National Liver Cancer Screening Trial

NCT06084234
Status at this site: Recruiting
View directory record Official record
Conditions
Carcinoma, Hepatocellular, Hepatitis B, Liver Cancer, Liver Cirrhosis
Interventions
GALAD, Liver Ultrasound with or without AFP
Diagnostic Test
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
5,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2034
U.S. locations
19
States / cities
Los Angeles, California • Redwood City, California • Roseville, California + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 14, 2026, 7:40 AM EDT
Active, not recruiting Phase 1 Interventional

A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies

NCT05453903
Site status not listed — check the official record
View directory record Official record
Conditions
Leukemia, Myeloid, Acute
Interventions
Azacitidine (AZA), Bleximenib, Cytarabine, Daunorubicin or Idarubicin, Venetoclax (VEN)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
12 Years and older
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
7
States / cities
Birmingham, Alabama • Duarte, California • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 15, 2026, 9:36 AM EDT
Recruiting Phase 4 Interventional

A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

NCT05201781
Status at this site: Recruiting
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Cilta-cel
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
295 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2041
U.S. locations
28
States / cities
Phoenix, Arizona • Duarte, California • San Francisco, California + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 15, 2026, 3:10 PM EDT

About this Massachusetts General Hospital institution page

What this page lists
ClinicalTrials.gov records that list Massachusetts General Hospital in Boston, MA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, trials led by Massachusetts General Hospital at any site, browse by condition, or browse by U.S. city.